Vaxcyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cost of Revenue	-	-	-	75	23	-
Gross Profit	-	-	-	-75	-23	-
Selling, General & Admin	138.17	129.37	92.9	60.7	39.81	25.26
Research & Development	1,093	794.31	476.64	332.34	169.45	78.41
Operating Expenses	1,231	923.68	569.55	393.04	209.26	103.67
Operating Income	-1,231	-923.68	-569.55	-468.04	-232.26	-103.67
Interest Expense	-	-	-	-	-0	-0.01
Interest & Investment Income	102.01	119.72	109.99	62.91	8.36	0.34
Currency Exchange Gain (Loss)	-	-	-	-	-	1.67
Other Non Operating Income (Expenses)	-19.32	37.33	-4.38	2.87	0.42	1.59
EBT Excluding Unusual Items	-1,148	-766.63	-463.93	-402.27	-223.49	-100.08
Gain (Loss) on Sale of Investments	-	-	-	-	-	0
Pretax Income	-1,148	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income	-1,148	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income to Common	-1,148	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	142	136	122	97	65	52
Shares Outstanding (Diluted)	142	136	122	97	65	52
Shares Change	4.84%	11.55%	25.57%	49.75%	24.95%	75.73%
EPS (Basic)	-8.07	-5.63	-3.80	-4.14	-3.44	-1.93
EPS (Diluted)	-8.07	-5.63	-3.80	-4.14	-3.44	-1.93
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-994.76	-712.55	-571.79	-364.67	-176.44	-127.95
Free Cash Flow Per Share	-6.99	-5.24	-4.69	-3.75	-2.72	-2.46
EBITDA	-1,208	-907.28	-562.54	-464.89	-229.42	-101.87
D&A For EBITDA	23.33	16.4	7	3.16	2.83	1.8
EBIT	-1,231	-923.68	-569.55	-468.04	-232.26	-103.67

SEC Filings: 10-K · 10-Q